Direct Biologics Reveals Successful Outcomes from EXIT COVID-19 Phase II Clinical Trial
Direct Biologics announced positive Phase II trial results for ExoFlo, a treatment for COVID-19 related ARDS, showing a 37.6% reduction in 60-day mortality and no adverse events. ExoFlo, derived from MSCs, offers anti-inflammatory and regenerative benefits without the drawbacks of stem cell transplantation. The company is preparing for a Phase III study amidst ongoing COVID-19 challenges.
Reference News
Direct Biologics announced positive Phase II trial results for ExoFlo, a treatment for COVID-19 related ARDS, showing a 37.6% reduction in 60-day mortality and no adverse events. ExoFlo, derived from MSCs, offers anti-inflammatory and regenerative benefits without the drawbacks of stem cell transplantation. The company is preparing for a Phase III study amidst ongoing COVID-19 challenges.